Shionogi
Shionogi & Co., Ltd., commonly known as Shionogi, is a prominent pharmaceutical company headquartered in Osaka, Japan. Founded in 1878, Shionogi has established itself as a leader in the pharmaceutical industry, focusing on research and development in areas such as infectious diseases, pain management, and central nervous system disorders. With a strong presence in Japan and expanding operations in North America and Europe, Shionogi is renowned for its innovative core products, including antiviral treatments and analgesics. The company’s commitment to advancing healthcare solutions has led to significant milestones, including the development of groundbreaking therapies that address unmet medical needs. Shionogi's dedication to quality and innovation has positioned it as a key player in the global pharmaceutical market, earning recognition for its contributions to public health and patient care.
DitchCarbon Score
How does Shionogi's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Shionogi's score of 66 is higher than 79% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Shionogi's reported carbon emissions
In 2023, Shionogi & Co., Ltd. reported total greenhouse gas emissions of approximately 214,942,000 kg CO2e. This figure includes Scope 1 emissions of about 40,373,000 kg CO2e, Scope 2 emissions of approximately 31,650,000 kg CO2e (market-based), and significant Scope 3 emissions totalling around 142,919,000 kg CO2e, primarily from purchased goods and services (about 81,528,000 kg CO2e). Shionogi has set ambitious climate commitments, aiming to reduce its absolute Scope 1 and 2 emissions by 46.2% by FY2030/31 from a FY2019/20 baseline. Additionally, the company targets a 20% reduction in Scope 3 emissions from purchased goods and services over the same timeframe. By 2050, Shionogi aims to achieve net-zero emissions across all scopes. The company has also established near-term goals to reduce Scope 1 and 2 emissions to near zero by 2025. These commitments align with the Science Based Targets initiative (SBTi) and reflect Shionogi's dedication to addressing climate change within the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 43,456,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 46,681,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 196,761,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Shionogi is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
